Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.38 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.38 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | EDNRB | P24530 | 1/20 | 0.38 |
| ▸ | EDNRA | P25101 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.37 |
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | TTR | P02766 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3760203 | 1.00 | ALDH1A1 (0.47) | ALDH1A1CYP3A4KCNH2PABPC1APOBEC3A | |
| SCHEMBL3207653 | 1.00 | ALDH1A1 (0.47) | ALDH1A1CYP3A4KCNH2PABPC1APOBEC3A | |
| SCHEMBL14064156 | 0.85 | ALDH1A1 (0.46) | ALDH1A1CYP3A4KCNH2PABPC1APOBEC3A | |
| SCHEMBL14631099 | 0.84 | HPGD (0.39) | ALDH1A1CYP3A4KMT2AKCNN4HSD17B10 | |
| SCHEMBL10411477 | 0.82 | OPRM1 (0.42) | ALDH1A1CYP3A4KCNH2KMT2AHSD17B10 | |
| SCHEMBL10411486 | 0.82 | OPRM1 (0.42) | ALDH1A1CYP3A4KCNH2KMT2AHSD17B10 | |
| SCHEMBL27282374 | 0.81 | ALDH1A1 (0.46) | ALDH1A1CYP3A4KCNH2PABPC1APOBEC3A | |
| SCHEMBL28159968 | 0.81 | ALDH1A1 (0.46) | ALDH1A1CYP3A4KCNH2PABPC1APOBEC3A | |
| SCHEMBL9607535 | 0.80 | ALDH1A1 (0.51) | ALDH1A1CYP3A4PABPC1APOBEC3AAPOBEC3G | |
| SCHEMBL9607539 | 0.80 | ALDH1A1 (0.51) | ALDH1A1CYP3A4PABPC1APOBEC3AAPOBEC3G |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7812179-B2 | Process for the preparation of atorvastatin and intermediates | APOTEX PHARMACHEM INC. (CA) | 2010-10-12 | — | — | US | claimed |
| US-20090131683-A1 | Process for the preparation of atorvastatin and intermediates | APOTEX PHARMACHEM INC. | 2009-05-21 | — | — | US | claimed |
| US-7429613-B2 | Process for the preparation of atorvastatin and intermediates | APOTEX PHARMACHEM INC. (CA) | 2008-09-30 | — | — | US | claimed |
| EP-1853559-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF ATORVASTATIN AND INTERMEDIATES | Apotex Pharmachem Inc. (CA) | 2007-11-14 | — | — | EP | claimed |
| US-20060252816-A1 | Process for the preparation of atorvastatin and intermediates | APOTEX PHARMACHEM INC. | 2006-11-09 | — | — | US | claimed |
| US-7112604-B2 | Process for the preparation of Atorvastatin and intermediates | APOTEX PHARMACHEM INC. (CA) | 2006-09-26 | — | — | US | claimed |
| US-20060194867-A1 | PROCESS FOR THE PREPARATION OF ATORVASTATIN AND INTERMEDIATES | APOTEX PHARMACHEM INC. | 2006-08-31 | — | — | US | claimed |
| WO-2006089401-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF ATORVASTATIN AND INTERMEDIATES | APOTEX PHARMACHEM INC. (CA) | 2006-08-31 | — | — | WO | claimed |
| US-9540307-B2 | Statins of omega-3 polyunsaturated acids for treating hypercholesterolemia | JIVA PHARMA, INC. (US) | 2017-01-10 | — | — | US | disclosed |
| US-9540307-B2 | Statins of omega-3 polyunsaturated acids for treating hypercholesterolemia | JIVA PHARMA, INC. (US) | 2017-01-10 | — | — | US | disclosed |
| US-9540307-B2 | Statins of omega-3 polyunsaturated acids for treating hypercholesterolemia | JIVA PHARMA, INC. (US) | 2017-01-10 | — | — | US | disclosed |
| US-20150322032-A1 | Statins of Omega-3 Polyunsaturated Acids for Treating Hypercholesterolemia | JIVA PHARMA, INC. (US) | 2015-11-12 | — | — | US | disclosed |
| US-20150322032-A1 | Statins of Omega-3 Polyunsaturated Acids for Treating Hypercholesterolemia | JIVA PHARMA, INC. (US) | 2015-11-12 | — | — | US | disclosed |
| US-20150322032-A1 | Statins of Omega-3 Polyunsaturated Acids for Treating Hypercholesterolemia | JIVA PHARMA, INC. (US) | 2015-11-12 | — | — | US | disclosed |
| EP-0353732-A2 | Fluoro-olefins, method for their preparation and their use | CIBA-GEIGY AG (CH) | 1990-02-07 | — | — | EP | disclosed |
| US-4897490-A | DERIVATIVES OF BETA-HYDROXY,OMEGA-DIPHENYL,TETRAZOL-5-YL ALK-OMEGA-ENOIC ACID, ESTER OR LACTONE | BRISTOL-MEYERS COMPANY (US) | 1990-01-30 | — | — | US | disclosed |
| US-RE33033-E | REACTING AND ALDEHYDE WITH ENOLATE OF AN ALKYLACETATE; HYDROLYSIS | MERCK & CO., INC. (US) | 1989-08-22 | — | — | US | disclosed |
| EP-0306649-A1 | 3,5-Dihydroxycarboxylic acids and their derivatives, processes for their preparation, their use as medicaments, pharmaceutic preparations and intermediate products | HOECHST AKTIENGESELLSCHAFT (DE) | 1989-03-15 | — | — | EP | disclosed |
| EP-0300249-A1 | 7-[1H-pyrrol-3-yl]-substituted 3,5-dihydroxy-heptane acids, their corresponding delta-lactones and salts, processes for their manufacture, their use as medicines, pharmaceutical preparations and intermediates | HOECHST AKTIENGESELLSCHAFT (DE) | 1989-01-25 | — | — | EP | disclosed |
| WO-1988006584-A1 | ANTIHYPERCHOLESTEROLEMIC TETRAZOLE COMPOUNDS | BRISTOL-MYERS COMPANY (US) | 1988-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131683-A1 | Process for the preparation of atorvastatin and intermediates | ACSL1, ACSL3, ACSL6 | ALDH1A1 104/4885CYP3A4 580/4885KCNH2 1540/4885 |
| US-20060194867-A1 | PROCESS FOR THE PREPARATION OF ATORVASTATIN AND INTERMEDIATES | ACSL1, ACSL3, ACSL6 | ALDH1A1 104/4885CYP3A4 580/4885KCNH2 1540/4885 |
| US-20060252816-A1 | Process for the preparation of atorvastatin and intermediates | ACSL1, ACSL3, ACSL6 | ALDH1A1 104/4885CYP3A4 580/4885KCNH2 1540/4885 |
| US-20150322032-A1 | Statins of Omega-3 Polyunsaturated Acids for Treating Hypercholesterolemia | HMGCR, ELOVL3, STARD3 | ALDH1A1 3793/4885CYP3A4 798/4885KCNH2 4499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.